We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Synairgen Plc | LSE:SNG | London | Ordinary Share | GB00B0381Z20 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.155 | 3.43% | 4.675 | 4.35 | 5.00 | - | 25,623 | 16:35:16 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 0 | -17.65M | -0.0876 | -0.52 | 9.1M |
Date | Subject | Author | Discuss |
---|---|---|---|
23/4/2020 21:12 | TVM Crookie V interesting: This indicates it could be used outside hospitals in the trial: Patients admitted to hospital due to the severity of their COVID-19 disease OR non-hospitalised patients from high-risk co-morbidity groups such as the >65-years of age, or those with hypertension, cardiovascular disease, diabetes or a chronic lung condition This is interesting as it means that the trial is on patients newly diagnosed: Principal exclusion criteria 1. > 24 hours after confirmation of SARS-CoV-2 infection | toffeeman | |
23/4/2020 21:09 | Well I held these when nobody else wanted them, so the potential has never escaped my attention. However my concern is more over the protocols that are required etc, and we have politics involved in pharma and data analysis, that to me could end up in a car crash. Or pretty much has Been so far. How would you expect these to manage or ayou just binary, sell a chunk at 80p and hold? | l0ngterm | |
23/4/2020 20:55 | Not sure if this has been posted before but has all granular details of the trial: hxxps://www.clinical Interesting numbers as 400 is listed across 20 sites. | crookie3634 | |
23/4/2020 20:54 | ->> L0ngterm I strongly believe SNG001 is going to work. There is so much circumstantial evidence that is positive which leads me to think the risk reward is excellent. Just IMHO and DYOR.. | nobbygnome | |
23/4/2020 20:50 | Watch today's interview with Richard! He knows where this is going and so do I! | likya123 | |
23/4/2020 20:48 | NobbyI have never seen you so positive on any share . Either positive or negative, what is driving you here? | l0ngterm | |
23/4/2020 20:37 | Nobby, “you’re the man” 👍🏼 | makendon | |
23/4/2020 20:35 | I emailed Jim Cramer from Sqawk on the Street on CNBC today extolling the virtues of SNG because they were talking about possible treatments, all American companies of course! | nobbygnome | |
23/4/2020 20:31 | Synairgen are simply in the right place at the right time! From lse board.. BloombergToday 20:29 They have just had an interview with Dr Joseph Weinstein basically just said that the world needs a treatment that's low pressure ventilation direct to the lungs! Naturally Bloomberg have now received a very factual and informative email from me pointing them in the direction of SNG | likya123 | |
23/4/2020 20:27 | Don’t see the late trades ? No big ones. Wish there were ! Edit. Of the buy variety | peachie 74 | |
23/4/2020 20:17 | Bit of a positive difference here though. SNG has already got successful 'form'. :o) From the RNS: ______ Two Phase II clinical trials in asthma showed that inhaled SNG001 treatment activated antiviral pathways in the lung along with improving lung function in patients with a respiratory viral infection. We have also shown that treatment with inhaled SNG001 reduced lung viral load and lung pathology in an in vivo swine flu driven model of viral pneumonia. At the time of the MERS-CoV outbreak in 2013, Synairgen collaborated with the National Institutes of Health (NIH) in the US to show that SNG001 could protect against MERS-CoV infection of lung cells in vitro. | jev1 | |
23/4/2020 19:40 | Don't start.... | waterloo01 | |
23/4/2020 19:39 | Like IMM.... | nobbygnome | |
23/4/2020 19:36 | PDT It's often the way with biotech. Built on hype, killed on data. | waterloo01 | |
23/4/2020 19:05 | FinnCap Short Interview with Richard Marsden, CEO, Synairgen Apr 23, 2020 | whites123 | |
23/4/2020 18:41 | University of Southampton are the lead investigators of the trial and I suspect they will have recruited the most | torreskid | |
23/4/2020 18:21 | I think RM in the interview was ackowledging SNG001 may not be the only COVID drug but will hopefully be effective with/without others. I s'pose we know that anyway, since the trial was clear that it was only being tested on particular inclusion criteria candidates, eg not in ICU /ventilated pt's etc If it does what we hope......supplying this to vulnerable / early onset viral pulmonary infections now and in the future is a massive breakthrough ! And maybe frontline staff for their protection ?? | 141jaffa | |
23/4/2020 18:04 | I think opinion is split..we'll soon know. | dovey21 | |
23/4/2020 17:54 | Gilead trial looks like it's not the great hope. That was the best hope in the markets to date so attention should shift back to other treatment options, aka SNG (and a few others) | waterloo01 | |
23/4/2020 17:51 | About 1m late reported trades - again. ;-) | wetdream | |
23/4/2020 17:29 | In relation to asthma - when is the inhaler supposed to be used? will it only be used during severe asthma attacks or used regularly like salbutamol? | asif12 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions